Overview
Recurrent rheumatic fever (RRF) encompasses a spectrum of inflammatory disorders characterized by periodic episodes of systemic inflammation affecting multiple organ systems. While historically associated with rheumatic fever following Group A Streptococcus (GAS) infection, the term RRF has evolved to include conditions like the TNF receptor-associated periodic syndrome (TRAPS), which present with overlapping clinical features such as recurrent fevers, arthralgia, and cutaneous manifestations. These syndromes often pose diagnostic challenges due to their episodic nature and variable clinical presentations, necessitating a thorough clinical evaluation and sometimes genetic testing for accurate diagnosis and management. Understanding the underlying pathophysiology, particularly in cases where genetic mutations play a role, is crucial for tailoring effective treatment strategies and improving patient outcomes.
Clinical Presentation
Recurrent rheumatic fever syndromes, including TRAPS, manifest with characteristic episodic symptoms that can significantly impact a patient's quality of life. The hallmark clinical features include recurrent episodes of fever, often accompanied by arthralgia or arthritis affecting multiple joints, typically in an asymmetric pattern. These episodes can vary in frequency and duration, ranging from days to weeks, and may be triggered by infections, stress, or other environmental factors. Cutaneous manifestations are also common, featuring erythematous rash, typically non-blanching and migratory, often seen on the trunk and extremities. Other frequent symptoms include myalgia, abdominal pain, and pleuritic chest pain, reflecting the multisystem involvement typical of these conditions.
Differential diagnosis is critical and should consider other periodic syndromes such as familial Mediterranean fever (FMF), hyperimmunoglobulinemia D syndrome (HIDS), and cryopyrin-associated periodic syndromes (CAPS). Distinguishing features may include specific triggers, family history, and genetic markers. For instance, TRAPS is often linked to mutations in the TNFRSF1A gene, which can be identified through molecular analysis, aiding in definitive diagnosis in patients who have remained undiagnosed for extended periods despite clinical suspicion [PMID:11700162]. Accurate clinical assessment, supported by genetic testing when indicated, is essential for timely intervention and management.
Diagnosis
Diagnosing recurrent rheumatic fever syndromes, particularly TRAPS, requires a multifaceted approach combining clinical evaluation with advanced diagnostic tools. The decision tree model highlighted in the literature demonstrates robust discriminative power, achieving an area under the receiver operating characteristic curve (AUC) of 96.3% in external validation, indicating high reliability in identifying patients with TRAPS [PMID:41423343]. This model, incorporating both clinical variables and genetic information, identified 91% of patients accurately, underscoring the importance of integrating genetic testing into diagnostic protocols.
Clinical criteria alone, while valuable, showed a slightly lower sensitivity at 88%, emphasizing their role as initial screening tools but highlighting the need for more precise diagnostic methods. Molecular analysis plays a pivotal role, especially in cases where genetic mutations, such as those in the TNF receptor gene (TNFRSF1A), are implicated. Identification of novel mutations in TNFRSF1A has been pivotal in diagnosing patients previously undiagnosed for decades, illustrating the transformative impact of genetic diagnostics in confirming TRAPS [PMID:11700162]. Therefore, a comprehensive diagnostic strategy should include detailed clinical history, physical examination, and targeted genetic testing to ensure accurate diagnosis and appropriate management.
Management
The management of recurrent rheumatic fever syndromes, particularly TRAPS, focuses on controlling inflammation and mitigating symptom severity to improve quality of life. Pharmacological interventions are central to this approach. One notable treatment modality involves the use of biologic agents that target the inflammatory pathways. For instance, etanercept, a recombinant fusion protein that acts as a soluble TNF receptor, has demonstrated efficacy in inducing prolonged remission in TRAPS patients. A case study reported significant improvement with a short course of etanercept, highlighting its potential as a therapeutic option [PMID:11700162]. The typical dosing regimen for etanercept often starts at 0.4 mg/kg twice weekly, adjusted based on response and tolerability.
Monitoring is crucial during treatment to assess efficacy and manage potential side effects. Regular follow-up appointments should include clinical evaluations to track symptom resolution and recurrence, as well as laboratory assessments such as inflammatory markers (e.g., C-reactive protein, ESR) to gauge the inflammatory burden. Periodic imaging studies may be necessary to monitor organ involvement, particularly in cases where musculoskeletal or cardiac symptoms are prominent. Long-term management strategies may also incorporate lifestyle modifications, including stress management and avoidance of known triggers, alongside pharmacological interventions to maintain remission and prevent acute episodes.
Prognosis varies among patients, influenced by the severity of symptoms, genetic mutation specifics, and adherence to treatment regimens. Early diagnosis and aggressive management can significantly improve outcomes, reducing the frequency and intensity of flare-ups and minimizing long-term complications. However, chronic inflammation and recurrent episodes can still pose challenges, necessitating ongoing vigilance and personalized care plans tailored to individual patient needs.
Key Recommendations
References
1 Papa R, Bovis F, Federici S, Palmeri S, Bustaffa M, Recchi G et al.. Decision Tree Analysis as a Preliminary Evidence-Based Tool for Identifying the Syndrome of Undifferentiated Recurrent Fever in Children Compared With Hereditary Recurrent Fevers and Periodic Fever, Aphthosis, Pharyngitis, and Adenitis Syndrome. Arthritis & rheumatology (Hoboken, N.J.) 2026. link 2 Simon A, van Deuren M, Tighe PJ, van der Meer JW, Drenth JP. Genetic analysis as a valuable key to diagnosis and treatment of periodic Fever. Archives of internal medicine 2001. link
2 papers cited of 3 indexed.